Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.03. | BeyondSpring GAAP EPS of -$0.21 | 1 | Seeking Alpha | ||
27.03. | BeyondSpring Inc. Full Year Loss Declines | 1 | RTTNews | ||
27.03. | BeyondSpring, Inc.: BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones | 105 | GlobeNewswire (Europe) | Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential... ► Artikel lesen | |
27.03. | BeyondSpring Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
BEYONDSPRING Aktie jetzt für 0€ handeln | |||||
27.03. | BeyondSpring, Inc.: BeyondSpring Files 2024 Annual Report on Form 10-K | 1 | GlobeNewswire (USA) | ||
27.03. | BeyondSpring Inc. - 8-K, Current Report | 3 | SEC Filings | ||
25.02. | BeyondSpring Inc. - 8-K, Current Report | - | SEC Filings | ||
28.01. | BeyondSpring sells stake in preferred shares of SEED Therapeutics for ~$35.4M | 1 | Seeking Alpha | ||
28.01. | BeyondSpring sells SEED Therapeutics shares for $35.4M | 2 | Investing.com | ||
28.01. | BeyondSpring, Inc.: BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies | 2 | GlobeNewswire (USA) | ||
28.01. | BeyondSpring Inc. - 8-K, Current Report | - | SEC Filings | ||
03.01. | BeyondSpring Inc. - 8-K, Current Report | - | SEC Filings | ||
11.11.24 | BeyondSpring, Inc.: BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior ... | 149 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
16.09.24 | BeyondSpring, Inc.: BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 | 207 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
16.09.24 | BeyondSpring, Inc.: BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 | 164 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
06.08.24 | BeyondSpring, Inc.: SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications | 219 | GlobeNewswire (Europe) | The SEED-Eisai Research Collaboration leverages Eisai's leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of up to $1.5 billion plus tiered... ► Artikel lesen | |
29.04.24 | BeyondSpring, Inc.: BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results | 238 | GlobeNewswire (Europe) | - BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and Mechanism... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,344 | +1,75 % | EQS-News: Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024 | EQS-News: Evotec SE
/ Schlagwort(e): Jahresbericht
Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024
17.04.2025... ► Artikel lesen | |
QIAGEN | 37,610 | +0,17 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
TEMPUS AI | 51,97 | +4,83 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 34,490 | +3,60 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen | |
BIONTECH | 102,20 | +0,79 % | Das ist die Nach-Oster-Chance! Evotec, Bayer, BioNTech, Defence Therapeutics und im Fokus | Donald Trump brüskiert seine internationalen Partner, beleidigt namhafte Amerikaner und entzieht Harvard langjährig zugesagte Fördermittel. Wer hätte das gedacht? Die neue US-Regentschaft entpuppt sich... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,675 | +1,89 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 | ||
ADMA BIOLOGICS | 22,240 | +2,25 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 41,590 | +1,02 % | Barclays maintains SpringWorks stock at Overweight, $63 target | ||
KYMERA THERAPEUTICS | 33,050 | +7,58 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader | Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June... ► Artikel lesen | |
ARCELLX | 63,43 | -0,22 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
CERO THERAPEUTICS | 1,070 | +32,99 % | CERo Therapeutics beginnt Phase-1-Studie für AML-Behandlung | ||
VERVE THERAPEUTICS | 5,720 | +4,95 % | Why Verve Therapeutics Zoomed 40% Higher This Week | ||
BB BIOTECH | 30,300 | +0,83 % | BB Biotech Aktie: Vor Quartalszahlen unter Druck | BB Biotech verzeichnet deutliche Kursverluste, doch Analysten halten an positiven Erwartungen fest. Die anstehenden Quartalszahlen könnten neue Impulse bringen. Die BB Biotech-Aktie zeigt sich vor der... ► Artikel lesen | |
BEAM THERAPEUTICS | 19,780 | -0,45 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
JANUX THERAPEUTICS | 31,500 | -0,41 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen |